Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 108 Cr.
- Current Price ₹ 217
- High / Low ₹ 316 / 111
- Stock P/E 36.6
- Book Value ₹ 41.3
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 5.25 times its book value
- Promoter holding has decreased over last quarter: -0.93%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 6m | Mar 2024 | TTM | |
|---|---|---|---|
| 8.03 | 18.96 | 22.00 | |
| 7.09 | 16.59 | 18.01 | |
| Operating Profit | 0.94 | 2.37 | 3.99 |
| OPM % | 11.71% | 12.50% | 18.14% |
| 0.01 | 0.03 | 0.06 | |
| Interest | -0.00 | 0.09 | 0.10 |
| Depreciation | -0.00 | 0.01 | 0.01 |
| Profit before tax | 0.95 | 2.30 | 3.94 |
| Tax % | 26.32% | 26.09% | |
| 0.70 | 1.70 | 2.94 | |
| EPS in Rs | 2.03 | 3.47 | 6.00 |
| Dividend Payout % | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 82% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Sep 2024 | |
|---|---|---|
| Equity Capital | 4.90 | 4.90 |
| Reserves | 13.44 | 15.35 |
| 1.61 | 1.55 | |
| 0.93 | 1.37 | |
| Total Liabilities | 20.88 | 23.17 |
| 0.05 | 0.06 | |
| CWIP | -0.00 | -0.00 |
| Investments | 0.43 | 0.44 |
| 20.40 | 22.67 | |
| Total Assets | 20.88 | 23.17 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | |
|---|---|---|
| -0.81 | ||
| -3.73 | ||
| 13.13 | ||
| Net Cash Flow | 8.59 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | 90.48 | |
| Inventory Days | 6.27 | |
| Days Payable | 1.16 | |
| Cash Conversion Cycle | 95.59 | |
| Working Capital Days | 145.35 | |
| ROCE % |
Documents
Announcements
-
Confirmation Of Non-Applicability Of Large Corporate Criteria As Per SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated November 26, 2018.
1d - Royal Sense confirms non-applicability of SEBI Large Corporate criteria as of 31 March 2025.
-
Non-Applicability Of Regulation 24A (2) Of SEBI (LODR) Regulation, 2015 For Submission Of Annual Secretarial Compliance Report
1d - Royal Sense exempt from Annual Secretarial Compliance Report for FY 2024-25 under SEBI SME rules.
-
Update on board meeting
1d - Board meeting postponed to 19 May 2025 to approve FY 2025 audited financial results.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015
9 May - Board meeting on May 16 to approve audited results for year ended March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Conversion of Securities
8 May - Allotment of 3.14 lakh equity shares on preferential basis raising Rs.3.08 crore from non-promoters.
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.